Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

Category	Detail
Condition	Psoriasis with ocular surface disease risk
Key Mechanisms	Biologic therapy associated with reduced risk of ocular surface diseases compared to nonbiologic systemic therapy
Target Population	Patients with psoriasis initiating systemic treatment
Care Setting	Outpatient dermatology and ophthalmology care

Biologic therapy linked to lower risk of dry eye disease, keratitis, and conjunctivitis.
Risk reductions observed as early as 6 months and sustained up to 10 years.
No consistent reduction in retinal or vitreous diseases overall; some regional differences noted.

Monitor for ocular surface diseases in patients with psoriasis receiving systemic therapy.

Consider biologic therapy to potentially reduce risk of ocular surface diseases in psoriasis patients.
Interdisciplinary management involving dermatology and ophthalmology is advised.

Regular ophthalmologic assessment for dry eye disease, keratitis, conjunctivitis, blepharitis, glaucoma, and cataract during treatment.

Observational data cannot establish causation; potential confounding by psoriasis severity and treatment adherence.
Possible misclassification due to ICD-10 coding and heterogeneity within diagnostic categories.

30,911 psoriasis patients initiating biologic therapy compared with 35,832 on nonbiologic systemic therapy.

Biologic therapy associated with lower ocular surface disease risk; outcomes may vary by biologic class and region.

Use propensity score matching and long-term follow-up to assess ocular outcomes in psoriasis treatments.
Interpret observational findings cautiously due to potential biases and confounding.
Tailor treatment decisions considering ocular risk profiles and interdisciplinary input.